Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients
- PMID: 22909997
- DOI: 10.1016/j.ejca.2012.07.017
Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients
Abstract
Purpose: Pancreatic cancer (PC) is associated with a dismal prognosis. Few studies have examined characteristics and outcome in an unselected population-based cohort of PC patients. Therefore, we investigated patient baseline characteristics, therapy choices and survival in a complete cohort of patients with PC.
Methods: All cases diagnosed with PC between 2007 and 2009 in the Region of Southern Denmark (pop: 1,200,000) were prospectively registered. Patient characteristics including performance status, information about haematology, liver function and therapy were retrieved from patient charts, and used to compare differently treated and untreated groups.
Results: Six-hundred-eighteen cases were registered as PC; 25 of which did not have adenocarcinomas. Patients were divided in 3 clinical groups based on initial therapy; group 1: resection (n=64), group 2: chemotherapy or chemo-radiotherapy (n=191), group 3: no tumour directed therapy (n=324). Median survival (mOS) (95% confidence interval (CI)) in the three groups was 25.7 months (18-30), 8.1 months (7.0-9.5) and 1.1 months (1.0-1.3) respectively. Three percent of patients participated in clinical trials. An evaluation of baseline factors prognostic value suggested that treated patients differed significantly from non-treated patients.
Conclusion: This study reports survival in treated groups comparable to results obtained from clinical trials with highly selected patients. However the majority of patients with PC do not receive cancer directed therapy. This group was significantly different in several baseline factors, which could suggest a different biology. Improving the outcome of PC patients calls for research into the large group of untreated patients, as only a minority of patients receive cancer directed therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer.Acta Oncol. 2014 Mar;53(3):385-91. doi: 10.3109/0284186X.2013.820839. Epub 2013 Aug 19. Acta Oncol. 2014. PMID: 23957622 Clinical Trial.
-
[Value of combined therapy in pancreatic cancer with a poor prognosis: analysis of 233 clinical cases].Zhonghua Yi Xue Za Zhi. 2009 Sep 15;89(34):2381-5. Zhonghua Yi Xue Za Zhi. 2009. PMID: 20137689 Chinese.
-
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.Am J Clin Oncol. 2008 Oct;31(5):446-53. doi: 10.1097/COC.0b013e318168f6c4. Am J Clin Oncol. 2008. PMID: 18838880
-
Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.Am Surg. 2000 Apr;66(4):378-85; discussion 386. Am Surg. 2000. PMID: 10776876 Review.
-
Neoadjuvant therapy for resectable pancreatic cancer.Surg Oncol Clin N Am. 2004 Oct;13(4):639-61, ix. doi: 10.1016/j.soc.2004.06.007. Surg Oncol Clin N Am. 2004. PMID: 15350939 Review.
Cited by
-
Molecular mediators of peritoneal metastasis in pancreatic cancer.Cancer Metastasis Rev. 2020 Dec;39(4):1223-1243. doi: 10.1007/s10555-020-09924-4. Epub 2020 Aug 11. Cancer Metastasis Rev. 2020. PMID: 32780245 Free PMC article. Review.
-
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure.Pleura Peritoneum. 2018 Nov 27;3(4):20180128. doi: 10.1515/pp-2018-0128. eCollection 2018 Dec 1. Pleura Peritoneum. 2018. PMID: 30911669 Free PMC article.
-
Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity Focused Ultrasound in Combination with Palliative Chemotherapy in Inoperable Pancreatic Cancer.J Clin Med. 2024 Jun 26;13(13):3717. doi: 10.3390/jcm13133717. J Clin Med. 2024. PMID: 38999283 Free PMC article.
-
A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening.Curr Oncol. 2025 Apr 11;32(4):225. doi: 10.3390/curroncol32040225. Curr Oncol. 2025. PMID: 40277782 Free PMC article.
-
Danish Pancreatic Cancer Database.Clin Epidemiol. 2016 Oct 25;8:645-648. doi: 10.2147/CLEP.S99471. eCollection 2016. Clin Epidemiol. 2016. PMID: 27822112 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical